Host: Brian P. McDonough, MD, FAAFP Guest: Silvio Inzucchi, MD Guest: Darren McGuire, MD, MHSc Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy

Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and

Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and

Faculty: Sagar Lonial, MD, FACP Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other

Faculty: Joshua Richter, MD Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other

Faculty: Joshua Richter, MD Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with

Faculty: Joshua Richter, MD Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other

Faculty: Joshua Richter, MD Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with

Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate

Listen now to 126 Future Now Show - Starfish MysteryWe made it back home from Canada by the skin of our teeth, just ahead of the massive Air Canada Flight Attendant’s strike, as were on one of the last flights out of Quebec province! <whew!> While in Canada we created some interviews for our show (see last two weeks shows), and now that we are back we’ll catch up on some significant Dr. Future news stories, starting with what appeared to be a body double for Putin at the recent

InTWISHthis week we look into the achievements ofJames Wattwho madea whole lot of things, despitenot inventing the steam engine. Then of course, there’s the news:ITALY: Government reverses appointment of vaccine hesitant members to National Immunisation Technical Advisory GroupITALY: The Natural Trap: How Conspiracy Beliefs Shape Our Health ChoicesSWEDEN: Renewed warning – Insulin instead of Ozempic in online ordersSWEDEN: Swedish PM Ulf Kristersson under fire for using AI in roleEUROPE: Hot summer:

Humanism and Life Skills: Embracing a Secular Worldview for Personal Growth

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Forat Lutfi, MD Guest: Nilanjan Ghosh, MD, PhD For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral networks, improving direct communication, and aligning on shared care responsibilities can

CME credits: 0.25 Valid until: 15-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-acromegaly-care-individualized-diagnosis-and-management-strategies/33027/ Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible

PhysOrg shares evidence that Neolithic humans — the farmers of the Stone Age — were a lot more into eating each other than previously thought: Francesc Marginedas at the Catalan … Read the rest “Our cannibal grandparents” The post Our cannibal grandparents first appeared on The Guild of Scientific Troubadours.

Eye On The Night Sky For Thursday, August 21

Show 570 - Whakapapa of Hopeful Bubbles - Samuel Mann is joined by Tim Lynch who brings us the second half of his conversation with Ihirangi Heke. As it is the last of our series on hope, Tim reflects on what we've learned. With a contribution from Tahu Mckenzie. This show was broadcast on OAR 105.4FM Dunedin - oar.org.nz

Lily Bentall, a PhD student in Neuroscience, talks about her research into trying to understand levodopa-induced dyskinesia, a widespread side effect of the use of levodopa to treat Parkinsons diseaseBroadcast on OAR 105.4FM Dunedin www.oar.org.nz

You know, I’ve been thinking a lot lately about how literature and art reflect what it means to be human. It’s fascinating how this idea, known as humanism, really shifted the way we create and appreciate our stories and images. When we talk about humanism in literature and art, what we’re really talking about is a focus on human experience—our emotions, thoughts, and potential—not just divine intervention or religious themes.

Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate